Cellular Biomedicine Group Completes Patient Treatment for Phase I Clinical Trial for Liver Cancer

Cellular Biomedicine Group (OTC: CBMG ) is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver